Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR

NCT02270463 is registered in ClinicalTrials.gov with Stemline Therapeutics, Inc. as lead sponsor.

NCT NCT02270463
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02270463 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Lead sponsor
Stemline Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Terminated
Start date
February 28, 2015
Completion date
December 31, 2019
Enrollment
16 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia